Maricann Group Inc. (CSE:MARI)(OTC: MRRCF) announced today that it has secured a second-site sales license for its location in Burlington, ON Canada through its wholly owned subsidiary Maricann Inc. The sales license is the second granted to Maricann by Health Canada, with the first applying to the company’s cultivation and processing facility in Langton, ON. With the granting of the new license, Maricann is shifting its client services, sales operations and research activities to Burlington.
The establishment of the Burlington site helps Maricann centralize and streamline numerous sales and marketing processes, including potential same day delivery within the Greater Toronto Area, and next day delivery across Canada. Maricann is now moving through the process of establishing its analytical laboratory functions at the Burlington site, to assist in medical research efforts. This is expected to help scale the business at a faster rate.
“The new headquarters in Burlington will centralize our sales, marketing and customer services operations under one roof, which will ultimately create greater efficiencies throughout the company. Importantly, In the near future, we expect to conduct analytical testing and bench research onsite. Overall, the move sets up Maricann for much greater future growth.” said Benjamin Ward, CEO of Maricann.
